Brostallicin (bro-STAL-iss-in) is a small molecule chemotherapeutic agent with a unique mechanism of action. In preclinical experimental tumor models, this novel synthetic second-generation DNA minor groove binder has shown potent cancer killing activity, and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death.
Triple-negative breast cancer lacks progesterone and estrogen receptors, and the HER2 biomarker that is present in most breast cancers, which makes standard therapy with hormone or targeted therapy ineffective. The interim results from a cooperative group sponsored Phase 2 clinical trial of brostallicin in combination with cisplatin for the treatment of women with metastatic triple-negative breast cancer were presented at the San Antonio Breast Cancer Symposium (SABCS) held Dec. 4-8, 2012. Final results of this trial are expected to be presented at the American Society of Clinical Oncology 2013 Annual Meeting. A follow-up randomized Phase 2 trial is in development.
Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer Active, not recruiting.